Radcliffe Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Radcliffe Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-102,974	Closed	-$1.03M	–	961
2022 Q3	$1.03M	Hold	102,974	–	–	0.02%	889
2022 Q2	$1.02M	Hold	102,974	–	–	0.02%	933
2022 Q1	$1.01M	Buy	102,974 +2,974	+3%	+$29.2K	0.02%	924
2021 Q4	$976K	Hold	100,000	–	–	0.03%	843
2021 Q3	$978K	Hold	100,000	–	–	0.03%	696
2021 Q2	$985K	Hold	100,000	–	–	0.03%	725
2021 Q1	$998K	Hold	100,000	–	–	0.04%	582
2020 Q4	$1M	Buy	+100,000	New	+$1.01M	0.06%	287

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Radcliffe Capital Management's EUCR Position: Q4 2022 in Review

Radcliffe Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 102,974 shares — an estimated $1.03M sold.

Radcliffe Capital Management first reported a position in EUCR in Q4 2020 and held it in 8 quarters. The position peaked at $1.03M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Radcliffe Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Radcliffe Capital Management sold 102,974 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $1.03M.
Radcliffe Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2020 and held it in 8 quarters.
Radcliffe Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1.03M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Radcliffe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.